Investor Presentaiton

Robust Pipeline Across Novel Therapeutics - Non-oncology Pipeline 1 commercialized assets, 1 assets in pivotal trials and 3 assets in clinical stage Lilly Products Target (s) Modality Status Therapeutic Area Commercial Rights Pre-clinical IND Approved Phase 1 Phase 2 Pivotal Phase 2/ Phase 3 NDA Launched SULINNOⓇ (adalimumab injection) TNF-alpha Monoclonal antibody Autoimmune Worldwide HoFH (Pivotal phase 2 ongoing) IBI-306 PCSK9 Monoclonal antibody Metabolic Mainland China, HK, Taiwan, Macau HeFH (Phase 3 met primary endpoint) nFH (Phase 3 ongoing) Obesity IBI-362 GLP1/GCGR (OXM3) polypeptide Metabolic Mainland China, HK, Taiwan, Macau Diabetics WAMD (Phase 2 onging) IBI-302 VEGF/Complement Fusion protein Ophthalmology Worldwide DME (to start Phase 2) Monoclonal antibody IBI-112 IL-23 p19 Autoimmune Worldwide Inflammatory enteritis and other autoimmune diseas Psoriasis (to start Phase 2) Listed drugs Biologics Small molecules Differentiated non-oncology pipeline represents long-term growth potential in major therapeutic areas including autoimmune, metabolic, and ophthalmology Innovent Confidential Copyright©2021 Innovent Biologics 16

View entire presentation